Listen: Moderna’s scant coronavirus data, the plight of the day trader, and the world’s dependence on biotech
When is a press release worth $5 billion? Can biotech stocks replace sports? And how will we know if a coronavirus vaccine actually works?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down the biggest news of the week: Moderna’s early-stage results from a coronavirus vaccine and the reaction from unsatisfied experts around the globe. Then, we examine how the world’s attention has turned to the biotech market, with volatile implications for every industry on the planet. Finally, we look back at the history of Moderna and the past controversies that set the stage for the company’s big moment.
